Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 


Genome-Scale Study ID’s Hundreds of Drug Targets for Huntington’s

Scientists searching for ways to develop treatments for Huntington’s disease (HD) just got a roadmap that could dramatically speed their discovery process.

Researchers at the Buck Institute have used RNA interference (RNAi) technology to identify hundreds of “druggable” molecular targets linked to the toxicity associated with the devastating, ultimately fatal disease.

The results from this unprecedented genome-scale screen in a human cell model of HD are published in the November 29, 2012 edition of PLoS Genetics. The work was is a collaboration between Buck Institute faculty members Robert E. Hughes, Ph.D., Sean Mooney, Ph.D., Lisa Ellerby, Ph.D. and Juan Botas, Ph.D. at the Baylor College of Medicine.

HD is a devastating and incurable progressive neurodegenerative genetic disorder that affects motor coordination and leads to severe physical and cognitive decline. Currently, there are about 30,000 people in North America diagnosed with HD and another 150,000 people at risk for developing the disease. The disease pathology stems from a mutation in the huntingtin gene (HTT), resulting in the accumulation of a toxic protein leading to neuronal cell death and systemic dysfunction. Buck Scientists screened more than 7,800 genes pre-selected as potential drug targets to identify modifiers of HD toxicity in human cells, using technology that silences specific genes prior to analysis.

Lead author Robert Hughes said that among the diverse range of modifiers identified, this study showed that RRAS, a gene involved in cell motility and neuronal development, is a potent modulator of HD toxicity in multiple HD models. “Our data indicates that the pathogenic effects of the HTT mutation on this pathway can be corrected at multiple intervention points and that pharmacological manipulation of RRAS signaling may confer therapeutic benefit in HD,” Hughes said. Follow up work on the RRAS pathway is now underway in the Hughes lab and in the lab of Buck faculty member Lisa M. Ellerby, PhD.

Hughes said many molecular hits identified in the screening were validated in human cell, mouse cell and fruit fly models of HD – and that all the data from the study will be available to the public. “Our hope is that HD researchers will look at these targets and find modifiers relevant to the areas they already work on,” said Hughes. “Ideally, pharmaceutical companies already working on some these pathways could build on their current knowledge and expertise by focusing their attention on the challenge to develop therapies for HD.”

Citation: “Miller JP, Yates BE, Al-Ramahi I, Berman AE, Sanhueza M, et al. (2012) A Genome-Scale RNA–Interference Screen Identifies RRAS Signaling as a Pathologic Feature of Huntington’s Disease. PLoS Genet 8(11): e1003042. doi:10.1371/journal.pgen.1003042”. Once the paper has been published, it will be accessible at

Contributors to the work:
Buck Institute researchers involved in the work include John Miller, Bridget E. Yates, Ari E. Berman, Francesco DeGiacomo, Cameron Torcassi, Jennifer Holcomb, Juliette Gafni, and Buck faculty members Robert E. Hughes, Lisa M. Ellerby and Sean D. Mooney. Other contributors include Ismael Al-Ramahi, Mario Sanhueza, Eugene Kim, Maria de Haro, and Juan Botas, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX. This work was supported by NIH NS040251, NIH NS055247, CHDI Inc., NIH NS042179, CHDI A-1979, NIH R01 LM009722 and NIH U54-HG004028, NIH T32 training grant AG000266, Hereditary Disease Foundation, John J. Wasmuth Postdoctoral Fellowship and Nathan Shock Center Grant P30AG025708.
About the Buck Institute for Research on Aging
The Buck Institute is the U.S.’s first and foremost independent research organization devoted to Geroscience – focused on the connection between normal aging and chronic disease. Based in Novato, CA, The Buck is dedicated to extending “Healthspan”, the healthy years of human life and does so utilizing a unique interdisciplinary approach involving laboratories studying the mechanisms of aging and those focused on specific diseases. Buck scientists strive to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer’s and Parkinson’s, cancer, cardiovascular disease, osteoporosis, macular degeneration, diabetes and stroke. In their collaborative research, they are supported by the most recent developments in genomics, proteomics, stem cell technology and bioinformatics. For more information:

Kris Rebillot | Newswise Science News
Further information:

More articles from Life Sciences:

nachricht Two decades of training students and experts in tracking infectious disease
27.11.2015 | Hochschule für Angewandte Wissenschaften Hamburg

nachricht Increased carbon dioxide enhances plankton growth, opposite of what was expected
27.11.2015 | Bigelow Laboratory for Ocean Sciences

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Tübinger Forscher entdecken neue Zelltypen im Gehirn

Untersuchung im Neocortex von Mäusen - Zusammenarbeit mit Wissenschaftlern aus Houston

Wissenschaftler aus Tübingen und Houston haben zahlreiche neue Zelltypen im Gehirn identifiziert. Im Neocortex von erwachsenen Mäusen führten sie erstmals eine...

Im Focus: Klimawandel: Forscher weisen dramatische Veränderung in den 1980er Jahren nach

Ende der 1980er Jahre erlebte die Erde eine dramatische Klimaveränderung. Sie umfasste die Tiefen der Ozeane ebenso wie die obere Atmosphäre und reichte vom Nord- bis zum Südpol. Ausgelöst durch den Ausbruch des Vulkans El Chichón in Mexico 1982 und verstärkt durch menschliches Handeln folgte daraus die größte Temperaturverschiebung der letzten 1.000 Jahre. Erstmals nachgewiesen hat dies ein internationales Forscherteam um Prof. Philip C. Reid von der Plymouth University und der Sir Alister Hardy Foundation for Ocean Science (UK). Die Ergebnisse wurden kürzlich in der Fachzeitschrift „Global Change Biology“ veröffentlicht.

Abrupte Klimaveränderungen haben oft dramatische Folgen für unseren Planeten. Dennoch sind sie in ihrer Art, ihrem Ausmaß und in ihrer Wirkungsweise meist nur...

Im Focus: Climate study finds evidence of global shift in the 1980s

Planet Earth experienced a global climate shift in the late 1980s on an unprecedented scale, fuelled by anthropogenic warming and a volcanic eruption, according to new research published this week.

Scientists say that a major step change, or ‘regime shift’, in the Earth’s biophysical systems, from the upper atmosphere to the depths of the ocean and from...

Im Focus: Innovative Photovoltaik – vom Labor an die Fassade

Fraunhofer ISE demonstriert neue Zell- und Modultechnologien an der Außenfassade eines Laborgebäudes

Das Fraunhofer-Institut für Solare Energiesysteme ISE hat die Außenfassade eines seiner Laborgebäude mit 70 Photovoltaik-Modulen ausgerüstet. Die Module...

Im Focus: Innovative Photovoltaics – from the Lab to the Façade

Fraunhofer ISE Demonstrates New Cell and Module Technologies on its Outer Building Façade

The Fraunhofer Institute for Solar Energy Systems ISE has installed 70 photovoltaic modules on the outer façade of one of its lab buildings. The modules were...

Alle Focus-News des Innovations-reports >>>



im innovations-report
in Kooperation mit academics

Bürger treffen Experten: Gespräch zu Chancen und Risiken der Nanotechnologie am 30.11.2015

27.11.2015 | Veranstaltungen

Arbeit in Sozialen Dienstleistungen - Welche Zukunft hat die Branche?

27.11.2015 | Veranstaltungen

Konzepte nutzergerechter Fahrerarbeitsplatzgestaltung

26.11.2015 | Veranstaltungen

Weitere VideoLinks >>>
Aktuelle Beiträge

Künstliche Herzklappe nach dem Vorbild der Natur

27.11.2015 | Förderungen Preise

Siemens liefert 126 Megawatt Onshore-Windleistung nach Schottland

27.11.2015 | Unternehmensmeldung

Hauptkläranlage Wien wird mit Siemens zum Ökokraftwerk

27.11.2015 | Energie und Elektrotechnik